- Dong Hoon SHIN, Ph.D.(adjunct professor)
- Faculty Appointment
- Associate Professor, Department of Cancer Biomedical Science, NCC-GCSP
Associate Scientist, Lung Cancer Branch
Research Institute, National Cancer Center
- Highest Academic Qualification
- Ph.D., Department of Pharmacology, College of Medicine, Seoul
National University, Seoul, Republic of Korea.
- Area of Expertise
- Work Experience
- 05/2009 – 06/2011., Thoracic head and neck Medical Oncology, M.D. Anderson Cancer
Center, Houston, USA.
07/2011 – 02/2014, Research professor, Department of Pharmacology, College of Medicine, Seoul National University, Seoul, Republic of Korea.
- Educational Background
- 02/2004 B.S., Life science, College of Natural science,
Ajou University, Su-won, Gyeonggi-do, Republic of Korea.
02/2006 M.A., Department of Pharmaceutical, College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
02/2009 Ph.D., Department of Pharmacology, College of Medicine, Seoul National University, Seoul, Republic of Korea.
- Research Interests (Please place in paragraph form)
- Research Themes
The main research interest in my laboratory is the study of anti-cancer drug resistance in lung cancer. Chemoresistance has two type’s resistances such as innate resistance and acquired resistance. Innate resistance is a hallmark of cancer. In recent years, acquired resistance has emerged as a serious challenge to targeted cancer therapy, which abolished the efficacy of successful targeting drugs. Cancer cells gain the resistance property through a variety of mechanisms, involving cellular intrinsic and extrinsic factors. The study of these kinds of resistance factors will lead to implementation of more effective treatment regimens, and also the design of new approaches to preventing the emergence of resistance.
Current Research Projects
1. The mammalian stress response gene sirtuin 1, SIRT1 plays a critical role in multiple aspects and give effects several key molecules of lung cancer drug resistance. Especially, we are doing search the role of SIRT1 in lung cancer driver mutations.
2. Growing tumors make hypoxia more and more. Conversely, this hypoxia makes result in more resistance cancer cells. In this point, we are interesting the role of stromal cells exposed by hypoxia of tumor microenvironment induced by cancer cells.
3. Several lung cancer driver mutations such as EGFR, KRAS, ALK and so on are identified. But, around 40% unknown factors still make lung cancer patient. Now, we are doing research finding new lung cancer driver mutation and identifying the function of new driver mutation.
- International Collaboration
- American Association for Cancer Research (AACR)
Member 11/2009 – Present
American Head and Neck Society (AHNS)
Member 08/2010 – Present